Brought to you by 
Roche buys sequencing firm 454 Life Sciences for $155mm
30 Mar 2007
Executive Summary
In order to put more focus on its mid-stage cancer drug candidates, CuraGen is selling Roche its DNA sequencing instruments business 454 Life Sciences for $154.9mm in cash. Roche will incorporate the acquired entity into Roche Diagnostics.
Deal Industry
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche buys sequencing firm 454 Life Sciences for $155mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice